title: Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
abstract: Both slow-release (SR) and regular-release (RR) metformin were effective in the treatment of type 2 diabetes mellitus. We compare the efficacy, safety, and effects on serum adipocytokines and inflammatory markers of both regimens in patients with type 2 diabetes mellitus. A prospective, randomized, double-blind study enrolled 55 patients with type 2 diabetes mellitus, which were randomly assigned to receive either metformin SR or RR (at a maximal dosage of 2000 mg/d for 12 weeks). Glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose, adipocytokines, C-reactive protein, and insulin resistance and pancreatic beta-cell function were measured before and after treatment. Significant decreases (P<.001) in mean HbA1c and fasting plasma glucose levels were observed in each group. However, the mean changes in HbA1c from baseline to end point in the 2 groups were not significantly different. Changes in metabolic parameters were similar except that a decreased total cholesterol level was observed in the metformin RR group. Neither regimen treatment had any influence on insulin resistance, but metformin RR improved beta-cell function. Neither regimen had an effect on serum adipocytokines or inflammatory markers. Once-daily metformin SR was as safe and effective as metformin RR in type 2 diabetic patients. Neither dosage form affected serum adipocytokines and inflammatory markers.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan, ROC.
authors.forename: Chang-Hsun
authors.initials: CH
authors.lastname: Hsieh
authors.forename: Chih-Tseung
authors.initials: CT
authors.lastname: He
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Lee
authors.forename: Ling-Yi
authors.initials: LY
authors.lastname: Wu
authors.forename: Yi-Jen
authors.initials: YJ
authors.lastname: Hung
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D002784:Cholesterol / Q000097:blood; D016207:Cytokines / Q000097:blood* / Q000378:metabolism; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D007249:Inflammation / Q000378:metabolism; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008687:Metformin / Q000008:administration & dosage* / Q000627:therapeutic use*; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D052242:Adiponectin; D001786:Blood Glucose; D002097:C-Reactive Protein; D002784:Cholesterol; D016207:Cytokines; D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D015850:Interleukin-6; D008687:Metformin; D054409:Nicotinamide Phosphoribosyltransferase; D014409:Tumor Necrosis Factor-alpha; C085455:nicotinamide phosphoribosyltransferase, human